CD8A and neoplasm: Additionaly, the frequency of tumor CD8+ and CD4+ cells that produce IFN-γ ex vivo in response to MCA205 cells in an ELISPOT assay was significantly increased after exposure to the combination therapy (online supplemental figure S8).